Companies · Biotechnology

Mevion Medical Systems, Inc.

LITTLETON · Biotechnology

Diligence memoA one-page analyst read on Mevion Medical Systems, Inc. — recommendation, valuation, rhythm, risks.
$95.3M
Total raised · real
3
Rounds
2.4×
Latest step-up
Top 11%
Sector rank · raised
Series C
Latest stage · inferred · Fri Jul 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Mevion Medical Systems, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.06× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era.
  • Within the normal band (106% of peer median) for its niche.
Dormant
  • Last raise 10.9 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Mevion Medical Systems, Inc. is one of 4291 Biotechnology companies tracked from LITTLETON. By capital raised it ranks among the largest (ahead of 90% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries A · 2011-03-08 Raised $11M (real) Modeled valuation $416M (est)$11M$416MSeries A2011Series B · 2012-01-12 Raised $25M (real) Modeled valuation $992M (est)$25M$992MSeries B2012Series C · 2015-07-24 Raised $59M (real) Modeled valuation $2.4B (est)$59M$2.4BSeries C2015+$25M+$59MCumulative $95M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$11.5M · 2011
Series B$25.0M · 2012
Series C$58.8M · 2015

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.

Modeled valuation trajectory
$2.4B
Base estimate est.
$182.0M
Conservative case
$6.3B
Upside case
$392.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $415.7M · 2011-03-082011Series B · modeled $992.2M · 2012-01-12Series C · modeled $2.4B · 2015-07-242015
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
6.0 yr
Elapsed time used
10.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
26 mo
Avg between rounds
$21.8M/yr
Capital velocity
15.3 yr
On record since
2011
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 13× above median
This company$95.3M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.3× above median
This company$58.8M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 38× above median
This company$2.4B
Sector median$64.2M

Raised more than 90% of sector peers (real $). Modeled value above 95% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #19 of 41.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Antigenics LLC/DE · Series C Raised $100.0M · modeled $4.1B (est)Naurex Inc. · Series C Raised $156.0M · modeled $3.3B (est)Fluidigm Corp · Series C Raised $111.0M · modeled $3.1B (est)Tengion Inc · Series C Raised $121.7M · modeled $3.0B (est)Spark Therapeutics, Inc. · Series C Raised $72.8M · modeled $3.0B (est)X-Co Holdings, LP · Series C Raised $71.0M · modeled $2.9B (est)REGENXBIO Inc. · Series C Raised $105.9M · modeled $2.9B (est)C4 Therapeutics, Inc. · Series C Raised $70.3M · modeled $2.9B (est)Intra-Cellular Therapies, Inc. · Series C Raised $70.3M · modeled $2.9B (est)Intellia Therapeutics, Inc. · Series C Raised $70.0M · modeled $2.9B (est)Chiasma Inc · Series C Raised $150.5M · modeled $2.9B (est)AveXis, Inc. · Series C Raised $65.0M · modeled $2.7B (est)Mevion Medical Systems, Inc. (this company) Raised $95.3M · modeled $2.4B (est)Mevion Medical Systems, Inc.
CompanyStageRaised · realValue · estvs peer med.
Antigenics LLC/DESeries C$100.0M$4.1B1.81×
Naurex Inc.Series C$156.0M$3.3B1.45×
Fluidigm CorpSeries C$111.0M$3.1B1.39×
Tengion IncSeries C$121.7M$3.0B1.34×
Spark Therapeutics, Inc.Series C$72.8M$3.0B1.32×
X-Co Holdings, LPSeries C$71.0M$2.9B1.29×
REGENXBIO Inc.Series C$105.9M$2.9B1.28×
C4 Therapeutics, Inc.Series C$70.3M$2.9B1.27×
Intra-Cellular Therapies, Inc.Series C$70.3M$2.9B1.27×
Intellia Therapeutics, Inc.Series C$70.0M$2.9B1.27×
Chiasma IncSeries C$150.5M$2.9B1.26×
AveXis, Inc.Series C$65.0M$2.7B1.18×
Mevion Medical Systems, Inc. this companySeries C$95.3M$2.4B1.06×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$11.5M2011-03-08$52.3M$415.7M90%
Series B$25.0M2012-01-12$138.9M$992.2M90%
Series C$58.8M2015-07-24$392.2M$2.4B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$11.5M2011-03-08
    • First recorded raise — entered as Series A.
  2. Series B$25.0M2012-01-12
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 2.2× larger than the prior — scaling up.
  3. Series C$58.8M2015-07-24
    • Raised again after 42 mo — slower than the ~14 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
Intelligence
2017 ~Q3
Modeled next raise · ~26mo cadence
$138.5M
Modeled next size est.range $90.0M$221.5M
2.4×
Last step-up
$21.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Wilson6 other2011-03
Mitchell Bloom5 other2015-07
Myles Greenberg5 other2011-03
Kenneth Gall4 other2011-03
Anders Hove3 other2011-03
Jay Moorin3 other2012-01
Marc Buntaine2 other2011-03
Cheng Lu1 other2015-07
Donald Melson2015-07
Jay Rao2011-03
Joseph Jachinowski2011-03
Paul Volcker2011-03
Peter D'Angelo2011-03
Stephen Buckley2015-07
Xiaowei Chang2015-07
Xuan Li2015-07
Registry & provenance

Mevion Medical Systems, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1326730
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Larimar Therapeutics, Inc.BiotechnologySeries C$201.0M$3.3Bnetwork1 shared operator · same sector · same stage
CARISMA Therapeutics Inc.BiotechnologySeries C$95.0M$1.3Bsame sector · same stage
DNA Research INST LLCBiotechnologySeries C$94.5M$3.7Bsame sector · same stage
Verve Therapeutics, Inc.BiotechnologySeries C$94.0M$3.1Bsame sector · same stage
Biotheryx, Inc.BiotechnologySeries C$93.8M$2.7Bsame sector · same stage
Deepcell, Inc.BiotechnologySeries C$96.9M$1.7Bsame sector · same stage
Dren Bio, Inc.BiotechnologySeries C$93.1M$1.3Bsame sector · same stage
Pulse Biosciences, Inc.BiotechnologySeries C$93.0M$1.4Bsame sector · same stage
Frequently asked
How much funding has Mevion Medical Systems, Inc. raised?
Mevion Medical Systems, Inc. has raised approximately $95.3M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Mevion Medical Systems, Inc.'s estimated valuation?
Provath's modeled valuation for Mevion Medical Systems, Inc. is approximately $2.4B (modeled range $182.0M–$6.3B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Mevion Medical Systems, Inc. at?
Mevion Medical Systems, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Jul 24.
What does Mevion Medical Systems, Inc. do and where is it based?
Mevion Medical Systems, Inc. operates in the Biotechnology sector, based in LITTLETON.
Explore related

See where Mevion Medical Systems, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Mevion Medical Systems, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.